GC
INO icon

Guggenheim Capital’s Inovio Pharmaceuticals INO Stock Holding History

Guggenheim Capital’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,274
Closed -$1.14M – 2167
2021
Q3 		$1.14M Buy
13,274
+505
+4% +$50.7K 0.01% 1350
2021
Q2 		$1.42M Buy
12,769
+440
+4% +$42.3K 0.01% 1289
2021
Q1 		$1.37M Sell
12,329
-514
-4% -$67.6K 0.01% 1227
2020
Q4 		$1.36M Buy
12,843
+1,831
+17% +$244K 0.01% 1170
2020
Q3 		$1.53M Buy
+11,012
New +$2.3M 0.01% 1008
2019
Q2 		– Sell
-48,168
Closed -$2.16M – 2141
2019
Q1 		$2.16M Buy
48,168
+32
+0.1% +$1.61K 0.02% 1031
2018
Q4 		$2.31M Buy
48,136
+6,068
+14% +$369K 0.02% 969
2018
Q3 		$2.81M Buy
42,068
+32
+0.1% +$1.78K 0.02% 1052
2018
Q2 		$1.98M Sell
42,036
-23
-0.1% -$1.27K 0.01% 1263
2018
Q1 		$2.38M Buy
+42,059
New +$2.28M 0.01% 1514
2015
Q1 		– Sell
-22,039
Closed -$2.43M – 3053
2014
Q4 		$2.43M Buy
22,039
+3,107
+16% +$380K 0.01% 1581
2014
Q3 		$2.24M Buy
+18,932
New +$2.36M 0.01% 1683
2014
Q1 		– Sell
-1,371
Closed -$191K – 3318
2013
Q4 		$191K Buy
1,371
+81
+6% +$8.11K ﹤0.01% 2860
2013
Q3 		$128K Hold
1,290
– – ﹤0.01% 2819
2013
Q2 		$49K Buy
+1,290
New +$39.1K ﹤0.01% 2906

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Guggenheim Capital's INO Position: Q4 2021 in Review

Guggenheim Capital sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 13,274 shares — an estimated $1.14M sold.

Guggenheim Capital first reported a position in INO in Q2 2013 and held it in 15 quarters. The position peaked at $2.81M in Q3 2018. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

  • Guggenheim Capital reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Guggenheim Capital sold 13,274 Inovio Pharmaceuticals shares in Q4 2021, an estimated $1.14M.
  • Guggenheim Capital first reported a position in Inovio Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Guggenheim Capital's Inovio Pharmaceuticals position peaked at $2.81M in Q3 2018.
  • 208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on Guggenheim Capital's 13F filing for Q4 2021, filed 14 Feb 2022.